Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H12I3N2O2.Na |
Molecular Weight | 619.9391 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CN(C)C=NC1=C(I)C(CCC([O-])=O)=C(I)C=C1I
InChI
InChIKey=ZFHZUGUCWJVEQC-UHFFFAOYSA-M
InChI=1S/C12H13I3N2O2.Na/c1-17(2)6-16-12-9(14)5-8(13)7(11(12)15)3-4-10(18)19;/h5-6H,3-4H2,1-2H3,(H,18,19);/q;+1/p-1
Molecular Formula | C12H12I3N2O2 |
Molecular Weight | 596.9493 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Iopanoic acid and ipodate salts have been used for oral cholangiography to visualize the biliary ducts. Ipodate salts have been used for the long-term treatment of Graves' disease and in hyperthyroidism. Ipodate reduced levels of T3 and T4 in the patients. Ipodate also inhibits the conversion of T4 to T3. It is not considered a first-line approach. Ipodate sodium lacks FDA approval for these uses. During investigation of mechanism of action was discovered, that binding of sodium ipodate with nuclear T3 receptors was not a prominent mechanism via which the drug attenuates T3 effects in vivo. Sodium ipodate could enhance T3 effects at the cellular level and that enhancement could not be reflected by routinely monitored serum TSH.
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
250 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5045427/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
IPODIC ACID blood | Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1600 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5045427/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
IPODIC ACID blood | Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5045427/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
IPODIC ACID blood | Canis lupus population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
A study of cardiac effects of thyroid hormones: evidence for amelioration of the effects of thyroxine by sodium ipodate. | 1984 Jun |
|
Use of oral cholecystography agents in the treatment of hyperthyroidism of subacute thyroiditis. | 2003 Mar |
|
Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. | 2007 Jun |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:05:39 GMT 2023
by
admin
on
Fri Dec 15 15:05:39 GMT 2023
|
Record UNII |
F316LLW9WW
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QV08AC08
Created by
admin on Fri Dec 15 15:05:39 GMT 2023 , Edited by admin on Fri Dec 15 15:05:39 GMT 2023
|
||
|
WHO-ATC |
V08AC08
Created by
admin on Fri Dec 15 15:05:39 GMT 2023 , Edited by admin on Fri Dec 15 15:05:39 GMT 2023
|
||
|
NCI_THESAURUS |
C1937
Created by
admin on Fri Dec 15 15:05:39 GMT 2023 , Edited by admin on Fri Dec 15 15:05:39 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000077382
Created by
admin on Fri Dec 15 15:05:39 GMT 2023 , Edited by admin on Fri Dec 15 15:05:39 GMT 2023
|
PRIMARY | |||
|
1221-56-3
Created by
admin on Fri Dec 15 15:05:39 GMT 2023 , Edited by admin on Fri Dec 15 15:05:39 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201243
Created by
admin on Fri Dec 15 15:05:39 GMT 2023 , Edited by admin on Fri Dec 15 15:05:39 GMT 2023
|
PRIMARY | |||
|
F316LLW9WW
Created by
admin on Fri Dec 15 15:05:39 GMT 2023 , Edited by admin on Fri Dec 15 15:05:39 GMT 2023
|
PRIMARY | |||
|
1033
Created by
admin on Fri Dec 15 15:05:39 GMT 2023 , Edited by admin on Fri Dec 15 15:05:39 GMT 2023
|
PRIMARY | |||
|
DTXSID9048271
Created by
admin on Fri Dec 15 15:05:39 GMT 2023 , Edited by admin on Fri Dec 15 15:05:39 GMT 2023
|
PRIMARY | |||
|
C65954
Created by
admin on Fri Dec 15 15:05:39 GMT 2023 , Edited by admin on Fri Dec 15 15:05:39 GMT 2023
|
PRIMARY | |||
|
214-945-3
Created by
admin on Fri Dec 15 15:05:39 GMT 2023 , Edited by admin on Fri Dec 15 15:05:39 GMT 2023
|
PRIMARY | |||
|
DBSALT001318
Created by
admin on Fri Dec 15 15:05:39 GMT 2023 , Edited by admin on Fri Dec 15 15:05:39 GMT 2023
|
PRIMARY | |||
|
SUB14256MIG
Created by
admin on Fri Dec 15 15:05:39 GMT 2023 , Edited by admin on Fri Dec 15 15:05:39 GMT 2023
|
PRIMARY | |||
|
9887
Created by
admin on Fri Dec 15 15:05:39 GMT 2023 , Edited by admin on Fri Dec 15 15:05:39 GMT 2023
|
PRIMARY | RxNorm | ||
|
23671932
Created by
admin on Fri Dec 15 15:05:39 GMT 2023 , Edited by admin on Fri Dec 15 15:05:39 GMT 2023
|
PRIMARY | |||
|
m6385
Created by
admin on Fri Dec 15 15:05:39 GMT 2023 , Edited by admin on Fri Dec 15 15:05:39 GMT 2023
|
PRIMARY | Merck Index | ||
|
106962
Created by
admin on Fri Dec 15 15:05:39 GMT 2023 , Edited by admin on Fri Dec 15 15:05:39 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |